Cannabidiol: Food or Drug? A Positioning
DOI:
https://doi.org/10.12970/2308-8044.2021.09.02Keywords:
Cannabidiol, Novel Food, Drug by presentation, narcotics, food supplementsAbstract
Products containing cannabidiol (CBD) such as CBD oil, are marketed in Europe as food and dietary supplements. They are also frequently advertised as potential treatments for serious illnesses. Applications for Novel Food Status are currently being processed in Europe. On closer scrutiny however, the basis for classifying CBD as a foodstuff is at best, questionable. The use of CBD in the management of severe disease is based on demonstrated pharmacological and clinical effects, which is clearly the domain of drug use. CBD lacks food-typical properties. Although CBD has a high level of toxicological safety even in high doses, this does not imply that it qualifies to be categorised as (novel) food simply because it has been proven to be safe. Herein, we examine the presentation of CBD-containing preparations with the background of European legislation.
References
Expert Committee on Drug Dependence. Cannabidiol (CBD). Critical review report https://www.who.int/medicines/access/ controlled-substances/CannabidiolCriticalReview.pdf. Fortieth Meeting, 4-7 June 2018. Geneva: WHO; 2018.
EFSA. Administrative guidance on the submission of applications for authorisations of a novel food pursuant to Article 10 of Regulation (EU) 2015/2283. EFSA Supporting Publication 2018; EB-1381. https://doi.org/10.2903/sp.efsa.2018.EN-1381
EFSA. Scientific Opinion on the risks for human health related to the presence of tetrahydrocannabinol (THC) in milk and other food of animal origin. EFSA J 2015; 13(6): 4141. https://doi.org/10.2903/j.efsa.2015.4141
BfR. Tetrahydrocannabinol levels are too high in many hemp-containing foods - health impairments are possible. BfR Opinion 2018; (No 034/2018 of 8. November 2018). https://www.bfr.bund.de/cm/349/tetrahydrocannabinol-levels-are-too-high-in-many-hemp-containing-foods-health-impairments-are-possible.pdf
ElSohly MA, Murphy TP, Khan I, Walker LW, Gul W. Analysis of cannabidiol, delta-9-tetrahydrocannabinol, and their acids in CBD oil/hemp oil products. Med Cannabis Cannabinoids. 2020; 3: 1-13. https://doi.org/10.1159/000509550
Davies C, Bhattacharyya S. Cannabidiol as a potential treatment for psychosis. Ther Adv Psychopharmacol 2019; 9: 2045125319881916. https://doi.org/10.1177/2045125319881916
Millar SA, Maguire RF, Yates AS, O'Sullivan SE. Towards Better Delivery of Cannabidiol (CBD). Pharmaceuticals (Basel) 2020; 13(9): 219. https://doi.org/10.3390/ph13090219
Nakano Y, Tahjima M, Sugiyama E, Sato VH, Sato H. Development of a novel nanoemulsion formulation to improve intestinal absorption of cannabidiol. Med Cannabis Cannabinoids 2019; 2: 35-42. https://doi.org/10.1159/000497361
Müller-Vahl K, Grotenhermen F. Cannabis und Cannabinoide in der Medizin. Berlin: Medizinisch-Wissenschaftliche Verlagsgesellschaft 2020.
Grotenhermen F, Russo E. Cannabis and Cannabinoids. Pharmacology, toxicology, and therapeutic potential. New York: Routledge 2002.
